BioCentury
ARTICLE | Finance

Highlights of weekly biotech stock moves

Regulatory, clinical and other milestones

December 17, 2012 8:00 AM UTC

Actelion Ltd. (SIX:ATLN) was down CHF1.34 to CHF44.99 on Friday after announcing FDA accepted for review an NDA for Opsumit macitentan to treat pulmonary arterial hypertension (PAH). A decision is expected around October 2013; the exact PDUFA date is not disclosed. Last week, the stock was down CHF1.81.

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) gained $0.60 (11%) to $5.84 on Friday after EMA's CHMP issued a positive opinion recommending Adasuve Staccato loxapine to treat mild to moderate agitation in adults with schizophrenia or bipolar disorder. The product is under FDA review with a Dec. 21 PDUFA date. Last week, the stock gained $0.65 (13%) to $5.84...